Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea

Allergan

Status: Completed

Conditions: Urinary Bladder, Overactive; Urinary Incontinence

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02010788

191622-134

Details and patient eligibility

About

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB) not adequately controlled by anticholinergic drugs.

Enrollment: 523 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients with urinary incontinence due to NDO or OAB treated with BOTOX® as per local standard of care in clinical practice.

Exclusion criteria

-None.

Trial design

523 participants in 1 patient group

BOTOX®

Description:

Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A